Published in final edited form as:

Bioorg Med Chem. 2017 May 01; 25(9): 2676–2678. doi:10.1016/j.bmc.2017.03.044.

Erratum to “Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors” [Bioorg. Med. Chem. 24 (2016) 3083–3092]

Sheng-Biao Wang^a, Mu-Tian Cui^a, Xiao-Feng Wang^{a,d}, Emika Ohkoshi^b, Masuo Goto^b, De-Xuan Yang^c, Linna Li^c, Shoujun Yuan^c, Susan L. Morris-Natschke^b, Kuo-Hsiung Lee^{b,e}, and Lan Xie^{a,b}

^aBeijing Institute of Pharmacology & Toxicology, 27 Tai-Ping Road, Beijing 100850, China

^bNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA

^cBeijing Institute of Radiation Medicine, 27 Tai-Ping Road, Beijing 100850, China

^dPharmacy Department, Urumqi General Hospital, Lanzhou Military Region, Urumqi 830000, China

^eChinese Medicine Research and Development Center, China Medical University & Hospital, Taichung, Taiwan

When this paper was first published there were errors in Tables 1 and 2. The data for the reference compounds staurosporine and paclitaxel were shifted one column to the left in error, and the activity entry given for staurosporine (0.083 micromolar) is incorrect. The correct tables are printed below.

The publisher apologises that these errors which were not rectified before publication.

Table 1
Biological activities and physicochemical properties of series 4 and 5

R ¹	R ³	IC ₅₀ (μM) ^a	Mer TK	A549	GI ₅₀ (μM) ^b					Properties ^c	
					KB	KB-vin	DU145	MV4-11	Aq Sol (μg/mL)	Log P	
4a		1.08		10.1	11.1	12.6	12.4	4.91	10.4	>5	
5a		1.14		9.4	11.7	10.1	10.2	2.70	1.11	>5	
4b		0.68		15.2	20.3	17.1	18.3	8.75	95.6	2.54	
5b		2.01		13.0	24.8	30.8	30.2	70.1	ND	ND	
4c		3.43		3.53	5.33	5.09	4.08	5.88	4.36	>5

	R ¹		R ³	IC ₅₀ (μM) ^a	Mer TK	GI ₅₀ (μM) ^b					Properties ^c	
						A549	KB	KB-vin	DU145	MV4-11	Aq Sol (μg/mL)	Log P
5c			Me	1.84		12.4	13.7	12.4	13.0	2.33 ^e	3.43	>5
4d			H	2.25		16.1	14.8	17.5	14.3	3.07	6.61	3.21
5d			Me	10.2		19.9	18.7	22.9	24.3	ND	ND	ND
4e			H	2.06		20.1	21.0	15.3	20.1	ND	ND	ND
5e			Me	>30	ND ^d	ND	ND	ND	ND	ND	ND	ND

R ¹	R ³	IC ₅₀ (μM) ^a	Mer TK	GI ₅₀ (μM) ^b					Properties ^c		
				A549	KB	KB-vin	DU145	MV4-11	Aq Sol (μg/mL)	Log P	
4f	H	3.56		13.0	13.3	13.4	13.0	<13.4	ND	ND	ND
5g	Me	>30		ND	ND	ND	ND	ND	ND	ND	ND
Staurosporine ^f		0.00081									
Paclitaxel (nM) ^f				4.9	2.6	948	2.6	ND			

^aThe concentration that inhibits 50% Mer tyrosine kinase.

^bThe concentration inhibits 50% human tumor cell growth, averaged values determined by at least three independent experiments.

^cActive compounds with IC₅₀ < 10 μM and GI₅₀ < 20 μM were measured by the methods in Ref. 19.

^dNot detected.

^eTested in human chronic myelogenous leukemia (K526) cells.

^fReference compounds as the positive control in related assays.

Table 2
Biological activities and physicochemical properties of series 6 and 7

R ¹	R ²	GI ₅₀ ^b (μM)							Property ^c	
		A549	KB	KB+vin	DUI45	MV4-11	Aq Sol (μg/mL)	Log P		
4a		10.1	11.1	12.6	12.4	4.91	10.4	>5		
6a		>31.3	>31.3	>31.3	>31.3	ND ^d	ND	ND		
6b		15.9	17.4	21.7	18.7	4.42	ND	ND		
6c		12.8	13.8	12.3	9.9	5.43	1.54	>5

R ¹	R ²	IC ₅₀ (μM) ^a	Mer. TK	A549	KB	KB-vin	GI ₅₀ ^b (μM)			Property ^c	
							DU145	MV4-11	Aq Sol (μg/mL)	Log P	
6d		1.24		14.8	12.1	13.6	14.3	3.00	3.10	3.95	
6e		2.90	COOH	28.7	25.2	19.8	27.3	7.50	ND	ND	
4b		0.68	OMe	15.2	20.3	17.1	18.3	8.75	95.6	2.54	
7a		1.72	CN	3.00	23.7	4.31	18.7	2.79	7.52	2.84	
7b		>30	NH ₂	17.1	19.7	18.7	20.8	ND	ND	ND	
7c		>30	F	19.3	17.1	24.2	20.6	ND	ND	ND

R ¹	R ²	IC ₅₀ (μM) ^a	Mer TK	GI ₅₀ ^b (μM)					Property ^c	
				A549	KB	KB-win	DU145	MV4-11	Aq Sol (μg/mL)	Log P
7d		7.84	F	4.3	2.9	2.5	4.2	ND	ND	ND
7e		>30	F	ND	ND	ND	ND	ND	ND	ND
7f		>30	NH ₂	ND	ND	ND	ND	ND	ND	ND
<hr/>										
Staurosporine ^e		0.00081								
Paclitaxel (nM) ^e				4.9	2.6	948	2.6			

^aIC₅₀ is concentration that inhibits 50% Mer tyrosine kinase.

^bGI₅₀ is concentration that inhibits 50% human tumor cell growth, and the values were averaged values determined by at least three independent experiments.

^cActive compounds with IC₅₀ < 10 μM and GI₅₀ < 20 μM were measured by the methods in Ref. 19.

^dNot detected.

Reference compounds as the positive control in related assays.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript